Hsp90 Regulates O-linked β-N-acetylglucosamine Transferase: a Novel Mechanism of Modulation of Protein O-linked β-N-acetylglucosamine Modification in Endothelial Cells

Overview

Journal Am J Physiol Cell Physiol

Publisher American Physiological Society

Specialties Cell Biology
Physiology

Date 2012 Apr 13

PMID 22496241

Citations 15

Authors

Fengxue Zhang

Connie M Snead

John D Catravas

Affiliations

Soon will be listed here.

Abstract

O-linked β-N-acetylglucosamine (O-GlcNAc) modification of proteins is involved in many important cellular processes. Increased O-GlcNAc has been implicated in major diseases, such as diabetes and its complications and cardiovascular and neurodegenerative diseases. Recently, we reported that O-GlcNAc modification occurs in the proteasome and serves to inhibit proteasome function by blocking the ATPase activity in the 19S regulatory cap, explaining, at least in part, the adverse effects of O-GlcNAc modification and suggesting that downregulating O-GlcNAc might be important in the treatment of human diseases. In this study, we report on a novel mechanism to modulate cellular O-GlcNAc modification, namely through heat shock protein 90 (Hsp90) inhibition. We observed that O-linked β-N-acetylglucosamine transferase (OGT) interacts with the tetratricopeptide repeat binding site of Hsp90. Inhibition of Hsp90 by its specific inhibitors, radicicol or 17-N-allylamino-17-demethoxygeldanamycin, destabilized OGT in primary endothelial cell cultures and enhanced its degradation by the proteasome. Furthermore, Hsp90 inhibition downregulated O-GlcNAc protein modifications and attenuated the high glucose-induced increase in O-GlcNAc protein modification, including high glucose-induced increase in endothelial or type 3 isoform of nitric oxide synthase (eNOS) O-GlcNAcylation. These results suggest that Hsp90 is involved in the regulation of OGT and O-GlcNAc modification and that Hsp90 inhibitors might be used to modulate O-GlcNAc modification and reverse its adverse effects in human diseases.

Citing Articles

FBXO31-mediated ubiquitination of OGT maintains O-GlcNAcylation homeostasis to restrain endometrial malignancy.

Zhang N, Meng Y, Mao S, Ni H, Huang C, Shen L Nat Commun. 2025; 16(1):1274.

PMID: 39894887 PMC: 11788441. DOI: 10.1038/s41467-025-56633-z.

Role of O-GlcNAcylation in Central Nervous System Development and Injuries: A Systematic Review.

Zhang L, Bai W, Peng Y, Lin Y, Tian M Mol Neurobiol. 2024; 61(9):7075-7091.

PMID: 38367136 DOI: 10.1007/s12035-024-04045-3.

Regulation of protein O-GlcNAcylation by circadian, metabolic, and cellular signals.

Liu X, Cai Y, Chiu J J Biol Chem. 2023; 300(2):105616.

PMID: 38159854 PMC: 10810748. DOI: 10.1016/j.jbc.2023.105616.

Nutrient-sensitive protein O-GlcNAcylation shapes daily biological rhythms.

Liu X, Chiu J Open Biol. 2022; 12(9):220215.

PMID: 36099933 PMC: 9470261. DOI: 10.1098/rsob.220215.

O-GlcNAcylation suppresses TRAP1 activity and promotes mitochondrial respiration.

Kim S, Backe S, Wengert L, Johnson A, Isakov R, Bratslavsky M Cell Stress Chaperones. 2022; 27(5):573-585.

PMID: 35976490 PMC: 9485411. DOI: 10.1007/s12192-022-01293-x.

References

Supko J, HICKMAN R, Grever M, Malspeis L . Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995; 36(4):305-15. DOI: 10.1007/BF00689048. View

Morimoto R, Kline M, Bimston D, Cotto J . The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. Essays Biochem. 1997; 32:17-29. View

Wang K, Ho S, Mao W, Huang P, Zhang F, Schwiebert E . Increased O-GlcNAc causes disrupted lens fiber cell differentiation and cataracts. Biochem Biophys Res Commun. 2009; 387(1):70-6. PMC: 2736685. DOI: 10.1016/j.bbrc.2009.06.132. View

Liu K, Paterson A, Zhang F, McAndrew J, Fukuchi K, Wyss J . Accumulation of protein O-GlcNAc modification inhibits proteasomes in the brain and coincides with neuronal apoptosis in brain areas with high O-GlcNAc metabolism. J Neurochem. 2004; 89(4):1044-55. DOI: 10.1111/j.1471-4159.2004.02389.x. View

Schulte T, Blagosklonny M, Ingui C, Neckers L . Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem. 1995; 270(41):24585-8. DOI: 10.1074/jbc.270.41.24585. View

Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm M, Fritz L . A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003; 425(6956):407-10. DOI: 10.1038/nature01913. View

Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Doyu M . Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein. J Mol Med (Berl). 2006; 84(8):635-46. DOI: 10.1007/s00109-006-0066-0. View

Haltiwanger R, Blomberg M, Hart G . Glycosylation of nuclear and cytoplasmic proteins. Purification and characterization of a uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase. J Biol Chem. 1992; 267(13):9005-13. View

Lazarus B, Love D, Hanover J . O-GlcNAc cycling: implications for neurodegenerative disorders. Int J Biochem Cell Biol. 2009; 41(11):2134-46. PMC: 2757632. DOI: 10.1016/j.biocel.2009.03.008. View

10.

Wiech H, Buchner J, Zimmermann R, Jakob U . Hsp90 chaperones protein folding in vitro. Nature. 1992; 358(6382):169-70. DOI: 10.1038/358169a0. View

11.

Kreppel L, Blomberg M, Hart G . Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem. 1997; 272(14):9308-15. DOI: 10.1074/jbc.272.14.9308. View

12.

Hanover J . Glycan-dependent signaling: O-linked N-acetylglucosamine. FASEB J. 2001; 15(11):1865-76. DOI: 10.1096/fj.01-0094rev. View

13.

Shafi R, Iyer S, Ellies L, ODonnell N, Marek K, Chui D . The O-GlcNAc transferase gene resides on the X chromosome and is essential for embryonic stem cell viability and mouse ontogeny. Proc Natl Acad Sci U S A. 2000; 97(11):5735-9. PMC: 18502. DOI: 10.1073/pnas.100471497. View

14.

Segnitz B, Gehring U . The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J Biol Chem. 1997; 272(30):18694-701. DOI: 10.1074/jbc.272.30.18694. View

15.

Whitesell L, Shifrin S, Schwab G, Neckers L . Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res. 1992; 52(7):1721-8. View

16.

Ochel H, Schulte T, Nguyen P, Trepel J, Neckers L . The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase. Mol Genet Metab. 1999; 66(1):24-30. DOI: 10.1006/mgme.1998.2774. View

17.

Kang B, Plescia J, Dohi T, Rosa J, Doxsey S, Altieri D . Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell. 2007; 131(2):257-70. DOI: 10.1016/j.cell.2007.08.028. View

18.

Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N . Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A. 1996; 93(25):14536-41. PMC: 26168. DOI: 10.1073/pnas.93.25.14536. View

19.

Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Sobue G . Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG). Ann N Y Acad Sci. 2006; 1086:21-34. DOI: 10.1196/annals.1377.012. View

20.

MEACHAM G, Patterson C, Zhang W, Younger J, Cyr D . The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol. 2001; 3(1):100-5. DOI: 10.1038/35050509. View